<div id="readability-page-1"><p>Merck KGaA Sponsored ADR ((MKKGY)) has held its Q1 earnings call. Read on for the main highlights of the call.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Merck KGaA’s latest earnings call struck a cautiously upbeat tone as management celebrated a return to organic growth, improving margins and stronger cash generation, while acknowledging FX drag, healthcare pressures and one‑off boosts in Electronics. Investors heard a story of underlying momentum and upgraded guidance, but also clear near‑term risks around currencies, product erosion and demand phasing.</p> <h2>Group Organic Growth and Profitability Improvement</h2> <p>Merck delivered around 2.9% organic sales growth and roughly 5% organic EBITDA pre growth, even though reported revenue declined on FX and portfolio effects. The underlying EBITDA pre margin improved by about 70 basis points to 29.8%, signaling better operating leverage despite the external headwinds.</p> <h2>Life Science Outperformance</h2> <p>Life Science was the standout, posting 8.3% organic sales growth, driven by a 16% surge in Process Solutions, which again topped EUR 1 billion in quarterly sales. Segment EBITDA pre grew about 7.4% organically with modest margin expansion of around 50 basis points, underscoring the resilience of this high‑quality earnings engine.</p> <h2>Electronics Growth in Semiconductor Materials</h2> <p>Electronics returned to organic growth with sales up 4.2%, led by Semiconductor Solutions, which grew roughly 7.5% on strong AI and advanced‑node demand. Segment EBITDA pre jumped more than 30% organically and the reported margin reached 34.6%, though management stressed that a portion of this improvement stems from non‑recurring items.</p> <h2>Upgraded Full‑Year and 2026 Guidance</h2> <p>Management raised its 2026 ambition, now targeting EUR 20.4–21.4 billion in sales and EUR 5.7–6.1 billion in EBITDA pre, implying organic sales growth of up to 3%. EPS pre guidance moved up to EUR 7.50–8.20, framing a scenario of modest top‑line growth, stable profitability and easing FX pressure versus prior assumptions.</p> <h2>Strong Cash Flow and Deleveraging</h2> <p>Operating cash flow climbed about 47% year on year to roughly EUR 818 million, reflecting a healthier cash conversion profile. Net financial debt edged down by around 3.5% to EUR 8.318 billion, helped by disciplined capex and setting up more balance‑sheet flexibility for future investment.</p> <h2>Strategic M&amp;A and Capability Expansion</h2> <p>The company closed the JSR acquisition in early April, expanding its downstream protein A chromatography capabilities and strengthening its bioprocess offering. Management reiterated a strategy focused on high‑growth value drivers, integrated workflow solutions and disciplined deal‑making, aiming to build platform businesses rather than one‑off revenue streams.</p> <h2>Dividend Approved</h2> <p>Shareholders approved a dividend of EUR 2.20 per share, signaling confidence in Merck’s cash generation and balance sheet. The payout underlines the group’s commitment to returning capital to investors while still funding growth in its core franchises.</p> <h2>Order Momentum and Book‑to‑Bill in Life Science</h2> <p>Life Science booking trends remained robust, with order intake keeping the book‑to‑bill comfortably above one, pointing to sustained demand. Management expects Process Solutions to track close to its midterm growth aspiration of around 10% over time, even if some Q1 stocking and phasing effects fade.</p> <h2>Reported Sales and FX/Portfolio Headwinds</h2> <p>On a reported basis, group net sales fell 2.8% to EUR 5.134 billion, as significant currency headwinds and portfolio changes masked underlying growth. FX shaved about 5.7% off EBITDA pre, and the divestment of Surface Solutions alone reduced Electronics’ reported sales by more than 10%.</p> <h2>Healthcare Sales Decline and Franchise Pressures</h2> <p>Healthcare organic sales dropped 3.4%, worse than previously hinted, mainly due to U.S. generic competition for Mavenclad. Oncology declined 4.9%, Neurology &amp; Immunology fell 9.2% amid interferon erosion and Fertility shrank 5.2% on Gonal‑f pricing pressure in the U.S., highlighting franchise‑specific headwinds.</p> <h2>Healthcare Profitability Compression</h2> <p>Healthcare EBITDA pre fell about 8% organically, and management expects further margin pressure through 2026 as high‑margin U.S. sales erode and FX weighs. Planned launch investments, including for new therapies, will lift R&amp;D intensity with guidance pointing to an organic EBITDA pre decline of 12% to 8% this year.</p> <h2>EPS Pre Materially Lower Year on Year</h2> <p>EPS pre slid to EUR 2.11 from EUR 3.12 a year earlier, even though organic EBITDA grew, reflecting adverse FX, portfolio shifts and an unfavorable sales mix. The decline underscores how strongly reported earnings are being shaped by non‑operational factors in the near term, despite improving underlying performance.</p> <h2>Electronics EBITDA Boosted by One‑Off Gains</h2> <p>Electronics’ strong EBITDA pre growth was flattered by roughly EUR 67–68 million in one‑time benefits, including proceeds from an OLED IP divestment and a gain linked to supplier mislabeling. While core demand, particularly in semiconductor materials, is improving, investors should adjust for these non‑recurring items when assessing margin trends.</p> <h2>Macro and Geopolitical Uncertainty</h2> <p>Management emphasized that FX remains a disproportionate headwind and that geopolitical developments, especially in the Middle East, could disrupt demand patterns and phasing. Some of the Q1 strength in Process Solutions reflected exceptional stocking, which may not repeat, adding an element of caution to the near‑term trajectory.</p> <h2>Forward‑Looking Guidance and Outlook</h2> <p>Merck’s upgraded guidance assumes modest organic growth at group level, rising contributions from Life Science and a gradual normalization in FX impact, while healthcare faces ongoing Mavenclad pressure. Segment guidance now points to solid mid‑single‑digit growth in Life Science, a decline but better‑than‑feared outlook in Healthcare and steady expectations in Electronics, with midterm targets reaffirmed.</p> <p>Merck’s earnings call painted a picture of a company leaning on Life Science and semiconductor materials to offset pressure in Healthcare and FX‑hit reported numbers. With stronger cash flow, higher guidance and clear strategic priorities, the investment case looks more constructive, though investors will need to monitor healthcare erosion, macro risks and the durability of the recent upturn in demand.</p></div>

MKKGY

<p>Merck KGaA's Q1 earnings call highlighted a cautious optimism with 2.9% organic sales growth and improved EBITDA margins despite currency and healthcare pressures. Life Science segment excelled with 8.3% growth, while Electronics saw a 4.2% increase. Management raised 2026 sales and EBITDA guidance, reflecting strong cash flow and a commitment to strategic M&A. However, healthcare sales declined 3.4%, impacting profitability. EPS pre dropped to EUR 2.11, influenced by non-operational factors. A dividend of EUR 2.20 per share was approved, indicating confidence in cash generation.</p>

Merck KGaA Earnings Call Signals Cautious Upswing